PTCT PTC Therapeutics, Inc.
Company Updates ·
Sephience revenue reached $182 million in the quarter, the company acquired ST-920 for $111.0 million upfront, and it now expects total revenue of $1.29 to $1.32 billion for 2026.
PTC says the rolling BLA for ST-920 is expected to be completed in the fourth quarter of 2026, with the goal of accelerated approval.
PTC Therapeutics will pay $111 million upfront and up to $100 million more in milestones for ST-920, subject to approval by the bankruptcy court.
PTC says the ST-920 rolling BLA will be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 if the acquisition closes.
PTC reported second quarter 2026 total revenue of $361 million, including $239 million of product revenue, and raised full-year product revenue guidance to $850 to $950 million.
PTC Therapeutics sold $550,000,000 of 0.0% convertible senior notes due 2031 through Morgan Stanley & Co. LLC as representative of the initial purchasers. The initial conversion price is about $107.48 a share.
Alethia Young resigned from the PTC Therapeutics board effective June 8, 2026, and will remain an advisor under a consulting agreement running through June 8, 2027.
PTC reported first quarter 2026 total revenue of $273 million and a net loss of $2.8 million, and raised full-year product revenue guidance to $750 to $850 million.
Former Censa securityholders holding about 90% of its equity gave up 8% to 12% net sales payments on sepiapterin. PTC will owe milestone payments of about $90.0 million each if sales reach set thresholds.
PTC paid about $225.0 million in cash to former Censa holders who gave up their share of sepiapterin sales, and it is still obligated to make five milestone payments of about $90.0 million each. The filing does not say what the rights were worth.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $455.2 million | $534.5 million |
| Net income (loss) | $682.6 million | -$363.3 million |
| Cash from operations | $711.2 million | -$107.7 million |
| Cash and equivalents | $984.6 million | $779.7 million |
| Short-term investments | $960.7 million | $360.0 million |
Our latest story on this, dated Aug 25, 2026: "PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 18, 2026: "PTC Therapeutics closes $550,000,000 convertible notes offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 18, 2026: "PTC Therapeutics closes $550,000,000 convertible notes offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 25, 2026: "PTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy". The story links the filing or release it is based on. Read the story.
PTC Therapeutics, Inc. trades under the ticker PTCT on NASDAQ.
PTC Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:BH3; FWB:BH3; GETTEX:BH3; HAM:BH3; HAN:BH3; MUN:BH3; SWB:BH3; TRADEGATE:BH3; XETR:BH3.
The SEC Central Index Key (CIK) for PTC Therapeutics, Inc. is 1070081. Its filings are on SEC EDGAR.
83,460,802 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-07-30.
Our directory records PTC Therapeutics, Inc. under United States.
Our directory classifies PTC Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for PTC Therapeutics, Inc. is US69366J2006.
aibio.space lists PTC Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
PTC Therapeutics, Inc. reported net income of $682.6 million for the fiscal year ended Dec 31, 2025, and generated $711.2 million of cash from operations, per its annual report to the SEC.
$455.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a bankruptcy filing. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio